[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Govindan R, Read W, Faust J, Trinkaus K, Ma MK, Baker SD, McLeod HL, Perry MC: Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. Oncology (Williston Park); 2003 Sep;17(9 Suppl 8):27-31
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report.
  • The outcomes for patients with metastatic or recurrent esophageal cancer are dismal, with 1-year survival rates of approximately 20%.
  • In this phase II study, we studied the combination of docetaxel (Taxotere) and irinotecan (CPT-11, Camptosar) in patients with metastatic or recurrent esophageal cancer.
  • Eligible patients included those with histologic or cytologic diagnosis of adenocarcinoma or squamous cancer of the esophagus or gastroesophageal junction who had received no previous chemotherapy for metastatic esophageal cancer.
  • Previous chemotherapy in the neoadjuvant or adjuvant setting was allowed.
  • Patients received irinotecan at 160 mg/m2 over 90 minutes followed by docetaxel at 60 mg/m2 intravenously over 1 hour, with chemotherapy cycles repeated every 21 days.
  • The median survival was 130 days, with three patients still alive at the time of this analysis.
  • There was no evidence of pharmacokinetic interaction, as systemic clearance of both drugs was similar to that seen after single-agent administration.
  • In conclusion, the regimen of docetaxel and irinotecan is active in metastatic or recurrent esophageal cancer.
  • However, this combination chemotherapy regimen has an unacceptable rate of febrile neutropenia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Recurrence. Survival Analysis. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14569845.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


2. Badreddine RJ, Prasad GA, Wang KK, Song LM, Buttar NS, Dunagan KT, Lutzke LS, Borkenhagen LS: Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus. Gastrointest Endosc; 2010 Apr;71(4):697-703
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus.
  • BACKGROUND: The incidence and risk factors for recurrence of dysplasia after ablation of Barrett's esophagus (BE) have not been well defined.
  • OBJECTIVE: To determine the rate and predictors of dysplasia/neoplasia recurrence after photodynamic therapy (PDT) in BE.
  • Entry histology, demographics, length of BE, presence and length of diaphragmatic hernia, EMR, stricture formation, nonsteroidal anti-inflammatory drug use, smoking, and the presence of nondysplastic BE or squamous epithelium were assessed for univariate associations.
  • Time-to-recurrence analysis was done by using Cox proportional hazards regression.
  • Median time to recurrence was 17 months (interquartile range 8-45 months).

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):403-9 [17325482.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):56-64; quiz 351-2 [18996379.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1585-94 [17461453.001]
  • [Cites] Gastrointest Endosc. 2000 Jun;51(6):659-63 [10840296.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2000 Jul;10(3):409-19 [10899255.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1661-8 [10925965.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):624-30 [10982754.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):554-8 [11323578.001]
  • [Cites] Dig Dis. 2000-2001;18(4):232-9 [11356995.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):225-9 [11774268.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1328-31 [12094845.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Mayo Clin Proc. 2002 Nov;77(11):1176-81 [12440553.001]
  • [Cites] Gastrointest Endosc. 2003 Aug;58(2):183-8 [12872083.001]
  • [Cites] Biomarkers. 2003 Nov-Dec;8(6):509-21 [15195681.001]
  • [Cites] Gut. 1990 Jan;31(1):4-10 [2318431.001]
  • [Cites] Am J Gastroenterol. 1996 Sep;91(9):1719-23 [8792687.001]
  • [Cites] Gastroenterology. 1998 Mar;114(3):448-55 [9496934.001]
  • [Cites] Gut. 1998 Dec;43(6):747-51 [9824599.001]
  • [Cites] Gastrointest Endosc. 1999 Jan;49(1):1-7 [9869715.001]
  • [Cites] Am J Med. 1999 Jun;106(6):642-9 [10378622.001]
  • [Cites] Gastrointest Endosc. 1999 Aug;50(2):165-72 [10425407.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Nov 15;20(10):1125-31 [15569115.001]
  • [Cites] J Pathol. 2005 Jan;205(1):57-64 [15586364.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Gastrointest Endosc. 2005 Apr;61(4):506-14 [15812401.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] World J Gastroenterol. 2005 Nov 14;11(42):6650-5 [16425359.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):60-6 [17185080.001]
  • [Cites] Gastrointest Endosc. 2007 Feb;65(2):185-95 [17258973.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1226-33 [17408660.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] Gut. 2007 Nov;56(11):1625-34 [17938435.001]
  • [Cites] Am J Gastroenterol. 2008 Jan;103(1):38-47 [18076737.001]
  • [Cites] Gut. 2008 Sep;57(9):1200-6 [18460553.001]
  • [CommentIn] Gastrointest Endosc. 2010 Apr;71(4):704-5 [20363412.001]
  • (PMID = 19959164.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK076845-04; United States / NCI NIH HHS / CA / R01 CA097048-05; United States / NCI NIH HHS / CA / R01CA097048; United States / NCI NIH HHS / CA / R01 CA111603; United States / NCI NIH HHS / CA / R03 CA135991; United States / NIDDK NIH HHS / DK / K08 DK076845-05; United States / NIDDK NIH HHS / DK / DK076845-04; United States / NCI NIH HHS / CA / R03CA135991-01; United States / NCI NIH HHS / CA / CA111603-05; United States / NIDDK NIH HHS / DK / K08 DK076845; United States / NCI NIH HHS / CA / CA097048-05; United States / NCI NIH HHS / CA / R01 CA111603-05; United States / NCI NIH HHS / CA / R01 CA097048; United States / NIDDK NIH HHS / DK / DK076845-05; United States / NCI NIH HHS / CA / R01 CA111603-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS248054; NLM/ PMC2981349
  •  go-up   go-down


3. Hage M, Siersema PD, Vissers KJ, Dinjens WN, Steyerberg EW, Haringsma J, Kuipers EJ, van Dekken H: Genomic analysis of Barrett's esophagus after ablative therapy: persistence of genetic alterations at tumor suppressor loci. Int J Cancer; 2006 Jan 1;118(1):155-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic analysis of Barrett's esophagus after ablative therapy: persistence of genetic alterations at tumor suppressor loci.
  • Barrett's esophagus (BE) is a major predisposing factor for the development of esophageal adenocarcinoma.
  • Current strategies for treatment of BE, both dysplastic and nondysplastic, include photodynamic therapy (PDT) and argon plasma coagulation (APC).
  • However, the effect of ablative therapy at the genetic level is unclear.
  • The tissue specimens obtained at baseline (t = 0) were analysed, as well as the first (t = 1; mean interval: 4 months) and last (t = 2; mean interval: 8 months) available biopsy with residual or recurrent BE after ablation.
  • Further, multiple genetic lineages before and after therapy were detected in 15 cases illustrating the multiclonal nature of BE.
  • We conclude that recurrent and/or persistent BE after ablative therapy still contains genetic alterations associated with malignant progression to cancer.
  • Therefore, the goal of treatment should be the complete elimination of Barrett's mucosa.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / drug therapy. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics. Genes, p53
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Photochemotherapy. Polymorphism, Genetic. Recurrence. Treatment Outcome


Advertisement
4. Anderson SE, Minsky BD, Bains M, Hummer A, Kelsen D, Ilson DH: Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer; 2007 Jun 18;96(12):1823-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined modality chemoradiation in elderly oesophageal cancer patients.
  • We present a single institution experience with 5-FU, mitomycin-C based chemoradiation for the primary treatment of elderly patients with oesophageal cancer.
  • Twenty-five patients with a median age of 77 years (range 66-88) with a diagnosis of stage II-III squamous cell or adenocarcinoma of the oesophagus were treated at Memorial Sloan Kettering from 1996 to 2001 with two cycles of concurrent 5-FU, mitomycin-C and 50.4 Gy.
  • Of the 23 patients evaluable for response, 17 patients (68%) had a negative post-treatment endoscopy and CT scan without evidence of progressive disease.
  • Eleven patients (44%) are alive and 10 (40%) remain without evidence of recurrent or progressive oesophageal cancer at a median follow-up of 35 months.
  • Similar survival was observed for patients with adenocarcinoma or squamous carcinoma.
  • Primary chemoradiation with two cycles of 5-FU, mitomycin-C, and 50.4 Gy in elderly patients is an active regimen with moderate toxicity, despite the advanced age and heavy comorbidity burden of this cohort.
  • Patients with local/regional oesophageal cancer with adequate functional status should not be excluded from potentially curative treatment based on age alone.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Mitomycin / administration & dosage. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2002 Mar;9(2):210-4 [11888881.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2109-16 [11596027.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2926-32 [12885811.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):45-52 [14701767.001]
  • [Cites] J Chronic Dis. 1987;40(7):705-12 [3110198.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):29-36 [1704362.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):685-8 [2004944.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1225-32 [7525520.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):333-8 [8625111.001]
  • [Cites] Ann Thorac Surg. 1997 May;63(5):1423-7 [9146337.001]
  • [Cites] J Clin Epidemiol. 1997 Jun;50(6):725-33 [9250271.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1387-92 [9338461.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):357-64 [9527058.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Oct;116(4):545-53 [9766581.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):269-76 [9788404.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):26-31 [9921970.001]
  • [Cites] Ann Thorac Surg. 2005 Feb;79(2):391-7; discussionn 391-7 [15680801.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] World J Gastroenterol. 2006 Feb 28;12(8):1296-9 [16534889.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):455-62 [10653860.001]
  • [Cites] J Am Coll Surg. 2000 May;190(5):562-72; discussion 572-3 [10801023.001]
  • [Cites] Ann Thorac Surg. 2001 Feb;71(2):414-8 [11235680.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]
  • [Cites] Dis Esophagus. 2003;16(2):90-3 [12823204.001]
  • (PMID = 17533399.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2359964
  •  go-up   go-down


5. Seitz JF, Duffaud F, Dahan L, Ries P, Ville E, Laugier R: [Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?]. Cancer Radiother; 2001 Nov;5 Suppl 1:107s-112s
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?].
  • [Transliterated title] Adénocarcinomes du bas oesophage et du cardia: quelle chimiothérapie ou chimioradiothérapie dans le traitement des récidives et des métastases?
  • Adenocarcinomas of esophagus and cardia represent in France approximately 20 to 40% of the esophagus cancers.
  • The standard of treatment of these metastatic adenocarcinomas is chemotherapy.
  • Three large randomized comparative studies, between chemotherapy and supportive care, showed that chemotherapy significantly extends the median of survival (from 3-4 months to 10-12 months) and improves the quality of life.
  • New drugs (such as docetaxel, CPT11, oxaliplatin) used alone or in combination, especially with 5U, are very promising.
  • Radio-chemotherapy is the preferred treatment for locoregional recurrences, because it improves dyphagia and enables to obtain complete tumor responses.
  • Current results from concomitant radio-chemotherapy studies for esophagus cancer, based on 5FU alone, 5FU-cisplatin or 5FU-mitomycin, given as preoperative treatment or as exclusive treatment, support to use radio-chemotherapy for the treatment of loco-regional recurrences after surgical resection.
  • Nevertheless, the optimal radio-chemotherapy schedule still remain to be defined (dose, duration, splitting of radiotherapy, choice of anticancer drugs).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cardia / pathology. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Deglutition Disorders / etiology. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Mitomycin / administration & dosage. Neoplasm Metastasis. Randomized Controlled Trials as Topic. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11797269.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW: Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res; 2006 Jul 15;12(14 Pt 1):4283-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.
  • Given recent reports of TKI-responsive cases of esophageal and pancreatic cancer, this study was designed to determine the prevalence of EGFR mutations in these gastrointestinal cancers.
  • EXPERIMENTAL DESIGN: We sequenced exons 18 to 21 of EGFR from 21 cases of Barrett's esophagus, 5 cases of high-grade esophageal dysplasia, 17 cases of esophageal adenocarcinoma, and 55 cases of pancreatic adenocarcinoma.
  • Subsets of esophageal (n = 7) and pancreatic cancer cases (n = 5) were obtained from patients who were subsequently treated with gefitinib or erlotinib-capecitabine, respectively.
  • RESULTS: Mutations of EGFR were identified in two esophageal cancers (11.7%), three cases of Barrett's esophagus (14.2%), and two pancreatic cancers (3.6%).
  • The mutations consisted of the recurrent missense L858R and in-frame deletion delE746-A750, previously characterized as activating EGFR mutations in non-small cell lung cancer.
  • We also identified the TKI drug resistance-associated EGFR T790M mutation in an untreated case of Barrett's esophagus and the corresponding adenocarcinoma.
  • CONCLUSION: The presence of activating mutations within EGFR in both esophageal and pancreatic adenocarcinomas defines a previously unrecognized subset of gastrointestinal tumors in which EGFR signaling may play an important biological role.
  • EGFR mutations in premalignant lesions of Barrett's esophagus also point to these as an early event in transformation of the esophageal epithelium.
  • The role of genotype-directed TKI therapy should be tested in prospective clinical trials.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93 [15731348.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2244-51 [15788673.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2493-501 [15710947.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2513-20 [15738541.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2879-82 [15837736.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3750-7 [15897572.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70 [15897464.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1081-6 [15851406.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e73 [15737014.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1334-42 [15956035.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5539-48 [16061871.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7096-101 [16103058.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7568-72 [16140919.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6838-45 [15998906.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6816-22 [16203769.001]
  • [Cites] Ann Oncol. 2005 Nov;16(11):1848-9 [16012179.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Oct;131(10):649-52 [16032426.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8081-92 [16204011.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8105-8 [16299242.001]
  • [Cites] Nat Genet. 2005 Dec;37(12):1315-6 [16258541.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8418-24 [16322304.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):963-9 [16152581.001]
  • [Cites] Oncogene. 2006 Feb 23;25(8):1205-15 [16205628.001]
  • [Cites] Cancer Biol Ther. 2006 Feb;5(2):152-5 [16357520.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4922-7 [17050876.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Science. 2002 Jul 5;297(5578):63-4 [12098689.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1980-7 [12743152.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4819-25 [14581353.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7241-4 [15492241.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):213-9 [8098013.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8195-203 [15623594.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2883 [15625347.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):226-35 [15665299.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):786-92 [15728811.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1368-71 [15746034.001]
  • (PMID = 16857803.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK071329; United States / NCI NIH HHS / CA / R01 CA115830; United States / PHS HHS / / P01 95281; United States / NCI NIH HHS / CA / R01 CA11530
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS519524; NLM/ PMC3807136
  •  go-up   go-down


7. Tew WP, Kelsen DP, Ilson DH: Targeted therapies for esophageal cancer. Oncologist; 2005 Sep;10(8):590-601
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies for esophageal cancer.
  • Esophageal cancer is a highly aggressive neoplasm.
  • In 2005, 14,520 Americans will be diagnosed with esophageal cancer, and more than 90% will die of their disease.
  • On a global basis, cancer of the esophagus is the sixth leading cause of cancer death worldwide.
  • In fact, gastric and esophageal cancers together accounted for nearly 1.3 million new cases and 980,000 deaths worldwide in 2000-more than lung, breast, or colorectal cancer.
  • Although esophageal squamous cell carcinoma cases have steadily declined, the incidence of gastroesophageal junction adenocarcinoma has increased 4%-10% per year among U.S. men since 1976, more rapidly than for any other cancer type, and parallels rises in population trends in obesity and reflux disease.
  • With advances in surgical techniques and treatment, the prognosis of esophageal cancer has slowly improved over the past three decades.
  • (b) cancer detection at an advanced stage, with over 50% of patients with unresectable disease or distant metastasis at presentation;.
  • (c) high risk for recurrent disease after esophagectomy or definitive chemoradiotherapy;.
  • (d) unreliable noninvasive tools to measure complete response to chemoradiotherapy; and (e) limited survival achieved with palliative chemotherapy alone for patients with metastatic or unresectable disease.
  • Clearly, additional strategies are needed to detect esophageal cancer earlier and to improve our systemic treatment options.
  • Over the past decade, the field of drug development has been transformed with the identification of and ability to direct treatment at specific molecular targets.
  • This review focuses on novel targeted treatments in development for esophageal squamous cell carcinoma and distal esophageal and gastroesophageal junction adenocarcinoma.
  • [MeSH-major] Esophageal Neoplasms / therapy
  • [MeSH-minor] Antibodies, Monoclonal / pharmacology. Clinical Trials as Topic. Cyclooxygenase 2 Inhibitors / pharmacology. Humans. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / metabolism. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Vascular Endothelial Growth Factor A / biosynthesis

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177283.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Number-of-references] 128
  •  go-up   go-down


8. Dunn JM, Mackenzie GD, Oukrif D, Mosse CA, Banks MR, Thorpe S, Sasieni P, Bown SG, Novelli MR, Rabinovitch PS, Lovat LB: Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy. Br J Cancer; 2010 May 25;102(11):1608-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy.
  • Image cytometric DNA analysis (ICDA) is an optical technique allowing visualisation of abnormal nuclei that may be undertaken on archival tissue.
  • Our aim was to determine the accuracy of ICDA vs FC, and evaluate DNA ploidy as a prognostic biomarker after histologically successful treatment with photodynamic therapy (PDT).
  • Aneuploidy post-PDT was highly predictive for recurrent HGD or cancer with a hazard ratio of 8.2 (1.8-37.8) (log-rank P=0.001).
  • CONCLUSIONS: ICDA is accurate for the detection of DNA ploidy abnormalities when compared with FC.
  • DNA ploidy by ICDA is a valuable prognostic biomarker after ablative therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Barrett Esophagus / drug therapy. Chromosome Aberrations. Esophagus / pathology. Image Cytometry. Photochemotherapy
  • [MeSH-minor] Aged. Case-Control Studies. Cytogenetic Analysis / methods. DNA, Neoplasm / genetics. Female. Flow Cytometry / methods. Humans. Hyperplasia / diagnosis. Hyperplasia / drug therapy. Hyperplasia / genetics. Male. Middle Aged. Neoplasm Staging. Ploidies. Prognosis. Recurrence. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1999 Dec;94(12):3413-9 [10606296.001]
  • [Cites] N Engl J Med. 2009 May 28;360(22):2277-88 [19474425.001]
  • [Cites] Gastroenterology. 1989 May;96(5 Pt 1):1249-56 [2703113.001]
  • [Cites] Anal Cell Pathol. 1995 Jan;8(1):67-74 [7734413.001]
  • [Cites] Lasers Med Sci. 2008 Apr;23(2):203-10 [17610005.001]
  • [Cites] J Histochem Cytochem. 1983 Nov;31(11):1333-5 [6619538.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1630-9 [11375945.001]
  • [Cites] Crit Rev Clin Lab Sci. 1994;31(1):1-34 [8049032.001]
  • [Cites] Cytometry. 1994 Dec 15;18(4):218-22 [7895528.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Cytometry. 1992;13(6):577-85 [1451590.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3089-96 [11095322.001]
  • [Cites] Cytometry. 1992;13(3):314-21 [1576895.001]
  • [Cites] Br J Surg. 1988 Aug;75(8):760-3 [3167523.001]
  • [Cites] Cytometry. 1995 Sep 15;22(3):181-9 [8556949.001]
  • [Cites] Arch Intern Med. 1991 Nov;151(11):2212-6 [1953225.001]
  • [Cites] Br J Obstet Gynaecol. 1994 Jul;101(7):621-5 [8043542.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] Lasers Med Sci. 2009 Sep;24(5):729-34 [19057983.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1595-607 [8156486.001]
  • [Cites] BMC Clin Pathol. 2008 May 30;8:5 [18513411.001]
  • [Cites] N Engl J Med. 1985 Oct 3;313(14):857-9 [4033716.001]
  • [Cites] Mod Pathol. 1991 Mar;4(2):178-82 [2047381.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):470-6 [18553366.001]
  • [Cites] Methods Cell Biol. 1994;41:263-96 [7861967.001]
  • (PMID = 20461081.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A9022
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2883155
  •  go-up   go-down


9. Marano S, Ruol A, Castoro C, Portale G, Cagol M, Alfieri R, Michieletto S, Ancona E: Adenocarcinoma of the proximal esophagus: report of 9 patients and review of the literature. Ann Surg Oncol; 2008 Oct;15(10):2910-4
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the proximal esophagus: report of 9 patients and review of the literature.
  • BACKGROUND: Adenocarcinoma of the proximal esophagus is a rare clinical entity, with only 28 cases described in the literature.
  • METHODS: Between 1980 and 2004, 1010 patients with esophageal or gastroesophageal junction adenocarcinoma (from a total of 4655 cancers, 3510 squamous and 1145 adeno) presenting at our department were retrospectively evaluated.
  • RESULTS: Nine patients (0.9%) had adenocarcinoma located in the proximal esophagus.
  • Three of them received endoscopic yttrium-aluminum-garnet (YAG)-laser therapy; 1 patient had feeding gastrostomy.
  • The other 5 patients (Group B) were given a first-line cytoreductive treatment: 4 had complete response, and 1 patient did not complete chemotherapy due to toxicity and underwent surgery for residual disease.
  • The median survival for these 5 patients receiving cytoreductive therapy was 36 months (range, 24-132 months).
  • For the 4 patients with complete clinical response to cytoreductive treatment, the median survival was 54 months (range, 24-132 months).
  • CONCLUSION: First-line chemoradiotherapy is an effective treatment for adenocarcinoma of the proximal esophagus.
  • Salvage surgery may be reserved for patients with incomplete response or recurrent disease.
  • [MeSH-major] Esophageal Neoplasms / pathology. Esophagectomy. Esophagogastric Junction / pathology. Salvage Therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18696159.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Wolfsen HC, Woodward TA, Raimondo M: Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma. Mayo Clin Proc; 2002 Nov;77(11):1176-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma.
  • OBJECTIVE: To evaluate our results using photodynamic therapy (PDT) for the treatment of dysplasia or superficial cancer (T1 N0 M0) in patients with Barrett esophagus.
  • PATIENTS AND METHODS: We retrospectively reviewed our clinical experience with 48 patients (34 patients with high-grade dysplasia and 14 patients with superficial cancer in Barrett esophagus) who had been referred for PDT.
  • Initial evaluation included computed tomography and standard and high-frequency catheter endosonography.
  • Patients were then followed up indefinitely every 3 to 6 months with computed tomography, endosonography, and endoscopic surveillance.
  • Complications included symptomatic strictures (11 patients), photosensitivity (7 patients), atrial fibrillation (1 patient) or recurrent congestive heart failure (1 patient), and self-limited esophageal perforation (1 patient).
  • Failure to ablate T1 N0 M0 adenocarcinoma occurred in 1 patient.
  • [MeSH-major] Adenocarcinoma / drug therapy. Barrett Esophagus / drug therapy. Barrett Esophagus / pathology. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology. Photochemotherapy / methods. Precancerous Conditions / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Esophagoscopy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Probability. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12440553.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Smith KJ, Williams J, Skelton H: Metastatic adenocarcinoma of the esophagus to the skin: new patterns of tumor recurrence and alternate treatments for palliation. J Cutan Pathol; 2001 Sep;28(8):425-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of the esophagus to the skin: new patterns of tumor recurrence and alternate treatments for palliation.
  • BACKGROUND: Esophageal cancer, particularly adenocarcinoma of the esophagus (ACE), has been steadily increasing in incidence in the United States.
  • However, today when patients with ACE are treated successfully with induction chemotherapy and radiation therapy, followed by surgical excision, ACE usually does not recur locally, but presents with metatastic disease.
  • We present a 62-year-old white male with ACE, which was treated with induction chemotherapy and radiation therapy followed by surgical excision.
  • RESULTS: The immunohistochemical profile was consistent with an esophageal origin showing positive staining with CK20 and CK7 as well as AE1/AE3 and EMA.
  • In addition, there was marked nuclear expression of p53, as well as membrane expression of c-erb-B2; consistent with progression of the disease and poor response to further cytotoxic therapeutic regimes.
  • CONCLUSIONS: With new therapeutic protocols, we can expect to see more metastatic disease with recurrences of ACE.
  • The histopathologic features and the immunohistochemical profile of the recurrent tumors may be helpful in determining alternate forms of therapy that either alone or in combination could be useful in palliation and delaying progression.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Palliative Care. Skin Neoplasms / secondary
  • [MeSH-minor] Biomarkers, Tumor / analysis. Combined Modality Therapy. Humans. Immunoenzyme Techniques. Male. Middle Aged


12. Mauer AM, Kraut EH, Krauss SA, Ansari RH, Kasza K, Szeto L, Vokes EE: Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol; 2005 Aug;16(8):1320-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus.
  • BACKGROUND: The aim of the study was to evaluate the efficacy and tolerability of the combination of oxaliplatin, fluorouracil and leucovorin in patients with advanced esophagus cancer.
  • PATIENTS AND METHODS: Thirty-five patients with recurrent or metastatic esophageal adenocarcinoma or squamous cell carcinoma were enrolled.
  • Up to one prior chemotherapy regimen was allowed.
  • Granulocyte colony stimulating factor was not routinely administered unless the patient developed febrile neutropenia or prolonged neutropenia.
  • Treatment was repeated every 14 days.
  • There was one treatment-related death secondary to neutropenic sepsis.
  • CONCLUSIONS: The combination of oxaliplatin, leucovorin, and fluorouracil shows significant anti-tumor activity and a favorable toxicity profile in patients with metastatic carcinoma of the esophagus.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15919687.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01CA63187-01
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Skehan SJ, Brown AL, Thompson M, Young JE, Coates G, Nahmias C: Imaging features of primary and recurrent esophageal cancer at FDG PET. Radiographics; 2000 May-Jun;20(3):713-23
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging features of primary and recurrent esophageal cancer at FDG PET.
  • Because of the poor prognosis for patients with esophageal cancer and the risks associated with surgical intervention, accurate staging is essential for optimal treatment planning.
  • Positron emission tomography (PET) with 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) is a useful adjunct to more conventional imaging modalities in this setting.
  • FDG PET is not an appropriate first-line diagnostic procedure in the detection of esophageal cancer and is not helpful in detecting local invasion by the primary tumor, and further studies are required to determine its efficacy in the detection of local nodal metastases.
  • In addition, FDG PET has proved valuable in determining the resectability of disease and allows scanning of a larger volume than is possible with computed tomography.
  • Recurrent disease is readily diagnosed and differentiated from scar tissue with FDG PET.
  • In addition, FDG PET may play a valuable role in the follow-up of patients who undergo chemotherapy and radiation therapy, allowing early changes in treatment for unresponsive tumors.
  • The management of most patients with esophageal cancer can be improved with use of FDG PET.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Blood Glucose / metabolism. Carcinoma, Squamous Cell / radionuclide imaging. Esophageal Neoplasms / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Tomography, Emission-Computed
  • [MeSH-minor] Adult. Aged. Esophagus / pathology. Esophagus / radionuclide imaging. Esophagus / surgery. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Radiographics. 2001 Mar-Apr;21(2):519 [11259713.001]
  • (PMID = 10835124.001).
  • [ISSN] 0271-5333
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Blood Glucose; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


14. Miller RC, Haddock MG, Gunderson LL, Donohue JH, Trastek VF, Alberts SR, Deschamps C: Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas. Dis Esophagus; 2006;19(6):487-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas.
  • IORT has potential utility in clinical situations, such as treatment of esophageal and gastric malignancies, in which the radiation tolerance of normal organs limits the dose that can be given with conventional radiotherapy techniques.
  • We reviewed the records of 50 patients who received IORT for locally advanced primary or recurrent gastric or esophageal adenocarcinomas deemed unresectable for cure.
  • IORT was given as a single fraction of electron beam radiotherapy (10-25 Gy) after maximal tumor resection: R0 in 42%, R1 in 46%, and R2 in 12%.
  • Forty-eight patients also received external beam radiotherapy (8-55 Gy), 46 received radiosensitizing chemotherapy, and nine received systemic chemotherapy after radiotherapy.
  • Of 42 patients who died, 37 died from cancer progression and three from multifactorial treatment toxicity.
  • Median survival for patients with recurrent disease versus primary disease was 3.0 years versus 1.3 years (P < 0.05), with a delay of metastatic failure in patients with recurrent tumors (P = 0.06).
  • IORT for locally advanced primary or recurrent gastric malignancies effectively decreases the risk of local failure.
  • For patients with isolated local recurrences, IORT may be effective salvage therapy.
  • However, more effective systemic therapy is needed as a component of treatment.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17069594.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Keeley SB, Pennathur A, Gooding W, Landreneau RJ, Christie NA, Luketich J: Photodynamic therapy with curative intent for Barrett's esophagus with high grade dysplasia and superficial esophageal cancer. Ann Surg Oncol; 2007 Aug;14(8):2406-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with curative intent for Barrett's esophagus with high grade dysplasia and superficial esophageal cancer.
  • BACKGROUND: Photodynamic therapy (PDT) has been used to palliate advanced, obstructing, or bleeding esophageal cancers (ECs) and Barrett's high-grade dysplasia (HGD).
  • Sixteen patients (32%) are alive without recurrence, 15 (30%) are living with residual or recurrent disease and have received additional PDT, and the remainder (38%) died of recurrent EC or other causes and had known recurrence.
  • Sixteen (32%) patients received adjuvant chemotherapy, radiation, or both.
  • Esophageal stricture occurred in 21 (42%) patients.
  • There was no procedure-related mortality.
  • CONCLUSIONS: PDT may represent a reasonable alternate to esophagectomy for high-risk patients with HGD or superficial esophageal cancer.
  • However, PDT appears to potentially cure approximately one-third of superficial esophageal cancers and provide local control of high-grade dysplasia in a similar subset of patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Barrett Esophagus / complications. Barrett Esophagus / drug therapy. Esophageal Neoplasms / drug therapy. Photochemotherapy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dihematoporphyrin Ether / therapeutic use. Endoscopy, Digestive System. Endosonography. Female. Follow-Up Studies. Humans. Male. Middle Aged. Photosensitizing Agents / therapeutic use. Survival Rate. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17534685.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


16. Williamson SK, McCoy SA, Gandara DR, Dakhil SR, Yost KJ, Paradelo JC, Atkins JN, Blanke CD, Abbruzzese JL, Southwest Oncology Group (SWOG): Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial. Am J Clin Oncol; 2006 Apr;29(2):116-22
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
  • OBJECTIVES: Metastatic esophageal carcinoma is an incurable disease with median survival duration of 6 to 8 months.
  • Based on preclinical data suggesting a dose-dependent synergy between gemcitabine and irinotecan we have conducted a phase II trial in patients with advanced or metastatic esophageal carcinoma.
  • METHODS: Patient eligibility included a diagnosis of squamous cell or adenocarcinoma of the esophagus/gastroesophageal (GE) junction, metastatic or recurrent disease, no CNS metastasis, no prior chemotherapy, prior adjuvant/neoadjuvant chemotherapy was allowed, no prior gemcitabine or irinotecan, performance status of 0 to 2 and adequate organ function.
  • There were 4 treatment-related deaths.
  • The median time to progression was 3.7 months.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16601427.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35262; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA45461; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / CA58416; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA76447; United States / NCI NIH HHS / CA / CA86780
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


17. Albertsson M, Johansson B, Friesland S, Kadar L, Letocha H, Frykholm G, Wagenius G: Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol; 2007;24(4):407-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer.
  • BACKGROUND: The purpose of these studies was to compare efficacy and toxicity of docetaxel alone with the combination of gemcitabine and docetaxel for treatment of metastatic esophageal carcinoma.
  • PATIENTS AND METHODS: These studies enrolled patients with histopathologically verified squamous cell carcinoma or adenocarcinoma of the esophagus or cardia.
  • They were scheduled for treatment with docetaxel 100 mg/m2 every third week as a 1-h infusion.
  • They were given docetaxel 30 mg/m2, administered as a 30-min i.v. infusion weekly for four times, followed by 2 weeks of rest, and gemcitabine starting with a dose of 750 mg/m2 (if well-tolerated 1,000 mg/m2) on days 1 and 15, followed by 3 weeks of rest.
  • Response was confirmed by computed tomography and assessed at 12 and 24 weeks.
  • Toxicity mainly involved leukopenia, which in some cases required hospitalization and treatment with antibiotics.
  • CONCLUSION: Docetaxel as a single agent is active in esophageal cancer, both in treatment naive and in previously treated patients with recurrent disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Deoxycytidine / analogs & derivatives. Esophageal Neoplasms / drug therapy. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2004 Jun;15(6):955-9 [15151954.001]
  • [Cites] Cancer Invest. 2003;21(6):887-96 [14735693.001]
  • [Cites] Med Oncol. 2003;20(1):19-24 [12665680.001]
  • [Cites] Eur J Cancer. 1997 Jul;33(8):1216-20 [9301445.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Radiother Oncol. 1988 Sep;13(1):41-6 [3187073.001]
  • [Cites] Cancer Invest. 2006 Jun-Jul;24(4):346-50 [16777685.001]
  • [Cites] J Thorac Cardiovasc Surg. 1968 Mar;55(3):396-404 [5644217.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Nov;8(11):1897-901 [7153100.001]
  • [Cites] Cancer Invest. 2004;22(5):670-7 [15581047.001]
  • [Cites] Ann Oncol. 1992 Dec;3(10):793-9 [1286042.001]
  • [Cites] J Natl Cancer Inst. 1994 Jul 20;86(14):1086-91 [7912736.001]
  • [Cites] Acta Radiol Oncol Radiat Phys Biol. 1979;18(2):103-12 [495189.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):221-31 [16770784.001]
  • [Cites] Cancer. 1981 Jul 15;48(2):329-35 [6453643.001]
  • [Cites] Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):22-5 [15685830.001]
  • [Cites] Dig Dis Sci. 2005 Dec;50(12 ):2218-23 [16416165.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1587-90 [7116290.001]
  • [Cites] Semin Oncol. 2005 Apr;32(2 Suppl 4):S39-51 [16015553.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1773-81 [15550582.001]
  • (PMID = 17917090.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


18. Imdahl A, Schöffel U, Ruf G, Hopf UT: [Preoperative chemoradiation in esophageal cancer: experience of a single center in 102 patients]. Zentralbl Chir; 2004 Oct;129(5):350-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative chemoradiation in esophageal cancer: experience of a single center in 102 patients].
  • [Transliterated title] Präoperative Radio-Chemotherapie beim Osophaguskarzinom: Erfahrungen eines Zentrums mit 102 Patienten.
  • The (dis-)advantages of preoperative chemoradiation in patients with esophageal cancer (EC) are still controversial as data are lacking showing a clear cut benefit.
  • Therefore, data of neoadjuvant therapy of our hospital have been analyzed.
  • Since 1994 102 patients with an EC (33 % adenocarcinoma, 67 % squamous cell cancer, scc) were operated after receiving preoperative chemoradiation (36 Gy radiation, 1.8 Gy/day for 4 weeks, 500 mg/m (2) 5-FU for 4 weeks and 20 mg/m (2) Cisplatin, day 1-5, week 1 and 4).
  • Operation was performed usually 8-10 weeks after treatment start.
  • In 11.7 % of patients with an adenocarcinoma a complete pathological response (CR, pT0N0M0) was observed and a pT0 stage in 20.6 %.
  • Postoperative morbidity was observed in 66 % (anastomotic leakage in 20 %, recurrent nerve palsy in 23 %).
  • Postoperative morbidity was observed in 87 % (anastomotic leakage in 16 %, recurrent nerve palsy in 32 %).
  • These results underline the benefit of neoadjuvant therapy in patients with a CR.
  • However, it remains open, whether neoadjuvant therapy leads to a downstaging of lymph node involvement, as histological confirmation in clinically positive lymph node is seldom performed prospectively.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Esophageal Neoplasms / surgery. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chi-Square Distribution. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Data Interpretation, Statistical. Esophagus / pathology. Female. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Radiation Dosage. Remission Induction. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15486784.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Ntoumazios SK, Voulgari PV, Potsis K, Koutis E, Tsifetaki N, Assimakopoulos DA: Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum; 2006 Dec;36(3):173-81
MedlinePlus Health Information. consumer health - Scleroderma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem.
  • This article reviews the esophageal involvement in SSc, emphasizing the gastroesophageal reflux, which is a common problem in SSc patients.
  • The keywords "systemic sclerosis," "esophageal involvement," "gastroesophageal reflux," "esophagitis," and "treatment" were used.
  • Although any part of the gastrointestinal tract can be involved, esophageal disease occurs in nearly all patients with SSc.
  • Common esophageal manifestations in SSc include motility abnormalities and gastroesophageal reflux (GER), Barrett's esophagus, adenocarcinoma, infectious esophagitis, and drug-induced esophagitis.
  • Extraesophageal manifestations of GER include mouth ulcers, chronic cough, hoarse voice, sore throat, pharyngitis, laryngospasm, asthma, and recurrent pneumonia.
  • Diagnostic procedures used in the investigation of esophageal involvement include barium esophagram, esophageal manometry, 24-hour ambulatory pH, and endoscopy.
  • Treatment of GER in SSc includes behavioral modification and medical therapy, mainly with proton pump inhibitors.
  • CONCLUSIONS: Esophageal involvement is frequent in SSc patients.
  • Appropriate treatment of esophageal involvement ameliorates symptoms and prevents complications.
  • [MeSH-major] Esophagitis / etiology. Esophagus / pathology. Gastroesophageal Reflux / epidemiology. Gastroesophageal Reflux / etiology. Scleroderma, Systemic / complications

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • Genetic Alliance. consumer health - Scleroderma.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17045629.001).
  • [ISSN] 0049-0172
  • [Journal-full-title] Seminars in arthritis and rheumatism
  • [ISO-abbreviation] Semin. Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 111
  •  go-up   go-down


20. Lew JI, Gooding WE, Ribeiro U Jr, Safatle-Ribeiro AV, Posner MC: Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma. Arch Surg; 2001 Jul;136(7):737-42; discussion 743
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma.
  • HYPOTHESIS: Long-term survival is rare in patients treated for esophageal carcinoma.
  • PATIENTS AND METHODS: Forty-four patients with carcinoma of the esophagus or gastroesophageal junction were prospectively entered into a phase II trial of preoperative 5-fluorouracil, cisplatin, and interferon alfa with concurrent external beam radiotherapy before esophagectomy.
  • Of these 17 patients, 15 show no evidence of recurrent disease.
  • Subsequent primary tumors have developed in 2 patients.
  • One patient had a recurrence at 11 months following initiation of treatment and remains disease-free 43 months postresection of a single brain metastasis.
  • Standard clinicopathologic parameters (age, sex, histologic findings, chemoradiotherapy regimen, and clinical and pathologic stages) were not significantly associated with a survival time of 3 years or longer (Fisher exact test, 2-tailed).
  • Median survival time for the long-term survivors has not been reached.
  • CONCLUSIONS: Long-term survival can be achieved in patients with esophageal carcinoma who undergo induction chemoradiotherapy and esophagectomy.
  • Recurrence is unlikely in patients who survive for 3 years or longer after undergoing this multimodality treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Esophagectomy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Dose Fractionation. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Interferon-alpha / administration & dosage. Male. Middle Aged. Neoadjuvant Therapy. Prospective Studies. Radiotherapy, Adjuvant. Remission Induction. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11448381.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Kodama M, Fujioka T: [Eradication therapy of Helicobacter pylori infection]. Rinsho Byori; 2001 Feb;49(2):130-4
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Eradication therapy of Helicobacter pylori infection].
  • Eradication therapy of H. pylori reduces the recurrence of gastro-duodenal ulcer, and improves gastritis histologically.
  • Recently, proton pump inhibitor(PPI) based triple therapy, that combining PPI, clarithromycin, amoxicillin is widely accepted throughout the world, and shows high eradication rate which ranged about 80-90%.
  • In Japan, one week triple therapy is recommended for the treatment of gastro-duodenal ulcer, though it is expected the improvement of recurrent peptic ulcer.
  • In the present studies, the rate of clarithromycin resistant strains has been increased gradually, and this fact may lead to the development of failure of PPI based triple therapy.
  • Another problem is suggested by several studies that gastro-esophageal reflux disease(GERD) may increase after successful eradication of H. pylori.
  • Reflux esophagitis and Barrett's esophagus are recognized as precancerous lesion of esophageal adenocarcinoma, but the association of newly occurrence of GERD after H. pylori eradication and increase of esophageal adenocarcinoma is not clear.
  • [MeSH-major] Helicobacter Infections / drug therapy. Helicobacter pylori

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11307304.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 7
  •  go-up   go-down


22. Swanson SJ, Batirel HF, Bueno R, Jaklitsch MT, Lukanich JM, Allred E, Mentzer SJ, Sugarbaker DJ: Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg; 2001 Dec;72(6):1918-24; discussion 1924-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma.
  • BACKGROUND: Several techniques for esophageal resection have been reported.
  • This study examines the morbidity, mortality, and early survival of patients after transthoracic esophagectomy for esophageal carcinoma using current staging techniques and neoadjuvant therapy.
  • METHODS: Three hundred forty-two patients had surgery for esophageal carcinoma between 1989 and 2000 at our institution.
  • Eighty-one percent (202) had induction chemotherapy (all patients with clinical T3/4 or N1).
  • Early postoperative complications included recurrent laryngeal nerve injury (14% [35]), chylothorax (9%, [22]), and leak (8%, [19]).
  • CONCLUSIONS: Total thoracic esophagectomy with node dissection for esophageal cancer appears to have acceptable morbidity and mortality with encouraging survival results in the setting of neoadjuvant therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Gastrostomy / methods. Lymph Node Excision / methods. Precancerous Conditions / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11789772.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


23. Tutuian R, Castell DO: Gastroesophageal reflux disease: natural history and long-term medical and surgical outcomes. Clin Cornerstone; 2003;5(4):51-7; discussion 58-60
MedlinePlus Health Information. consumer health - GERD.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Persistent untreated GERD can lead to esophageal strictures, premalignant Barrett's esophagus, and an increased risk of adenocarcinoma of the esophagus.
  • Currently, the most effective medical treatment targets gastric acid suppression, allowing healing of erosive/peptic lesions and controlling symptoms.
  • Most patients take over-the-counter medication or are successfully treated by their primary care physician.
  • Gastroenterologists and gastrointestinal surgeons see patients with complications, refractory symptoms despite acid-suppressive therapy, or atypical symptoms.
  • Medical therapy can heal 80% to 100% of patients with erosive esophagitis with 30% to 60% of patients reporting sustained resolution of heartburn.
  • Surgery may be offered to patients with GERD as an alternative to long-term antireflux medication.
  • Careful selection of appropriate surgical candidates is important, and the risk of developing new or recurrent symptoms requiring medication should be disclosed to patients contemplating the surgical alternative.
  • [MeSH-major] Gastroesophageal Reflux / drug therapy. Gastroesophageal Reflux / surgery

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15101495.001).
  • [ISSN] 1098-3597
  • [Journal-full-title] Clinical cornerstone
  • [ISO-abbreviation] Clin Cornerstone
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antacids; 0 / Gastrointestinal Agents; 0 / Histamine H2 Antagonists; 0 / Proton Pump Inhibitors
  • [Number-of-references] 27
  •  go-up   go-down


24. Bizekis C, Kent MS, Luketich JD, Buenaventura PO, Landreneau RJ, Schuchert MJ, Alvelo-Rivera M: Initial experience with minimally invasive Ivor Lewis esophagectomy. Ann Thorac Surg; 2006 Aug;82(2):402-6; discussion 406-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our standard approach involves laparoscopic and thoracoscopic mobilization of the esophagus with a cervical esophagogastric anastomosis.
  • The planned approach included a totally laparoscopic abdominal procedure and either a minithoracotomy or thoracoscopy.
  • Indications for esophagectomy included short segment Barrett's esophagus with high-grade dysplasia or resectable adenocarcinoma of the gastroesophageal junction (GEJ) with minimal proximal esophageal extension. .
  • Twenty-five patients (50%) received either preoperative chemotherapy or chemoradiation.
  • There was one nonemergent conversion to an open procedure during laparoscopy.
  • Three patients (6%) developed an anastomotic leak; all were successfully managed nonoperatively.
  • Four patients (8%) developed postoperative pneumonia.
  • There were no recurrent laryngeal nerve injuries.
  • This approach minimizes the degree of gastric mobilization, almost eliminates recurrent laryngeal nerve injury and pharyngeal dysfunction, and allows additional gastric resection margin in the case of cardia extension of GEJ tumors.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16863737.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


25. Nakajima S, Hattori T: Active and inactive gastroesophageal reflux diseases related to Helicobacter pylori therapy. Helicobacter; 2003 Aug;8(4):279-93
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active and inactive gastroesophageal reflux diseases related to Helicobacter pylori therapy.
  • We systematically reviewed the literature on gastroesophageal reflux disease (GERD) related to Helicobacter pylori therapy, and classified the GERD according to various aspects.
  • Preexisting GERD is active GERD before H. pylori therapy, and a substantial proportion of the GERD patients improve after successful H. pylori therapy.
  • If the GERD does not persist or recur after cessation of acid-suppressive therapy combined with H. pylori therapy, it may have been cured (cured GERD).
  • If it recurs, it may have been masked by acid-suppressive therapy and unmasked with cessation of the therapy (pharmacologically masked and unmasked GERD).
  • Newly developed GERD after successful H. pylori therapy is a kind of unmasked GERD arising after cure of infection (de novo unmasked GERD).
  • Preexisting GERD is not a reason to avoid eradication therapy.
  • De novo unmasked GERD develops in a substantial proportion of patients with cured infection.
  • The possible mechanism is increased acid exposure in the esophagus due to gastric acid increase, which is caused by a loss of neutralizing effect by ammonia, normalized cytokine-acid suppression and improvement of corpus atrophy.
  • De novo unmasked GERD is important because GERD is recurrent and may induce adenocarcinoma of the esophagus.
  • Eradication therapy is recommended irrespective of the possibility that de novo unmasked GERD may have a slight increase of the risk of esophageal adenocarcinoma.
  • [MeSH-major] Gastroesophageal Reflux. Helicobacter Infections / drug therapy
  • [MeSH-minor] Esophageal Neoplasms / etiology. Humans. Stomach Neoplasms / prevention & control

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12950600.001).
  • [ISSN] 1083-4389
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 77
  •  go-up   go-down


26. Kolh P, Honore P, Degauque C, Gielen J, Gerard P, Jacquet N: Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up. Eur J Cardiothorac Surg; 2000 Sep;18(3):293-300
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up.
  • METHODS: From January 1990 to December 1998, 130 patients underwent oesophageal resection for malignancy.
  • Indications were squamous cell carcinoma in 69 patients and adenocarcinoma in 61.
  • There were 84 subtotal oesophagectomies, with anastomosis in the neck in 44 patients and at the thoracic inlet in 40, and 46 distal oesophageal resections.
  • Postoperative complications occurred in 40 patients (31%), respectively, in ten (26%) and 30 (33%) patients after colonic and gastric transplants (P=0.48), and were pulmonary insufficiency or infection in 29 patients, anastomotic fistula in six, myocardial infarction in five, recurrent nerve palsy in four, renal insufficiency in three, and cerebrovascular accident in one.
  • The incidence of postoperative pulmonary complications was 70% (21/30 patients) in the subgroup who received preoperative radiochemotherapy, as compared to 11% (5/44 patients) in the subgroup of comparable staging, but without preoperative treatment (P<0.001).
  • Our results suggest that preoperative neoadjuvant treatment significantly increases postoperative pulmonary complications.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Colon / transplantation. Esophageal Neoplasms / surgery. Esophagus / surgery. Stomach / surgery
  • [MeSH-minor] Anastomosis, Surgical / methods. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagectomy. Female. Hospital Mortality. Humans. Male. Middle Aged. Palliative Care. Reoperation. Retrospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / surgery. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10973538.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


27. Peters JH: Progress in outlining the frequency and risk of recurrent neoplasia after ablation of Barrett's esophagus. Gastrointest Endosc; 2010 Apr;71(4):704-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress in outlining the frequency and risk of recurrent neoplasia after ablation of Barrett's esophagus.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / epidemiology. Barrett Esophagus / drug therapy. Barrett Esophagus / etiology. Endoscopy, Digestive System. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / epidemiology. Hematoporphyrin Photoradiation. Neoplasm Recurrence, Local / epidemiology. Precancerous Conditions / drug therapy. Precancerous Conditions / epidemiology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cross-Sectional Studies. Esophagus / pathology. Female. Follow-Up Studies. Hernia, Hiatal / complications. Hernia, Hiatal / epidemiology. Humans. Male. Middle Aged. Risk Factors. Smoking / adverse effects. Smoking / epidemiology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Gastrointest Endosc. 2010 Apr;71(4):697-703 [19959164.001]
  • (PMID = 20363412.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down






Advertisement